526 related articles for article (PubMed ID: 15117925)
1. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.
Alhambra A; Cuadros JA; Cacho J; Gómez-Garcés JL; Alós JI
J Antimicrob Chemother; 2004 Jun; 53(6):1090-4. PubMed ID: 15117925
[TBL] [Abstract][Full Text] [Related]
2. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011.
Bouchillon SK; Badal RE; Hoban DJ; Hawser SP
Clin Ther; 2013 Jun; 35(6):872-7. PubMed ID: 23623624
[TBL] [Abstract][Full Text] [Related]
4. Correlation of TEM, SHV and CTX-M extended-spectrum beta lactamases among Enterobacteriaceae with their in vitro antimicrobial susceptibility.
Manoharan A; Premalatha K; Chatterjee S; Mathai D;
Indian J Med Microbiol; 2011; 29(2):161-4. PubMed ID: 21654112
[TBL] [Abstract][Full Text] [Related]
5. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
Susić E
Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
[TBL] [Abstract][Full Text] [Related]
7. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
Tängdén T; Adler M; Cars O; Sandegren L; Löwdin E
J Antimicrob Chemother; 2013 Jun; 68(6):1319-26. PubMed ID: 23478794
[TBL] [Abstract][Full Text] [Related]
8. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
10. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Hu Z; Chu Y; Chen S; Cao B; Su J; Gui B; Duan Q; Zhang S; Shao H; Kong H; Badal RE; Xu Y
Antimicrob Agents Chemother; 2016 Jan; 60(1):245-51. PubMed ID: 26482308
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Taneja N; Rao P; Arora J; Dogra A
Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858
[TBL] [Abstract][Full Text] [Related]
15. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
[TBL] [Abstract][Full Text] [Related]
16. [Patterns of susceptibility to antibiotics of Enterobacteriaceae causing intra-abdominal infection in Spain: SMART 2003 study outcomes].
Baquero F; Cercenado E; Cisterna R; de la Rosa M; García-Rodríguez JA; Gobernado M; Pérez JL; Manchado P; Martín R; Pascual A; Picazo J; Prats G; Rubio C; Snyder TA; Sanz-Rodríguez C
Rev Esp Quimioter; 2006 Mar; 19(1):51-9. PubMed ID: 16688292
[TBL] [Abstract][Full Text] [Related]
17. Activity of ertapenem, ciprofloxacin, ceftriaxone, piperacillin-tazobactam, and ampicillin-sulbactam against 12 common clinical isolates of community-acquired bacteremia.
Hwang KP; Tang YF; Shen YH
J Microbiol Immunol Infect; 2009 Oct; 42(5):433-8. PubMed ID: 20182674
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
Demir T; Buyukguclu T
Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
Cuevas O; Cercenado E; Gimeno M; Marín M; Coronel P; Bouza E;
Diagn Microbiol Infect Dis; 2010 Jul; 67(3):251-60. PubMed ID: 20542206
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
